Yes. As of September 2026, Biogen Inc. (BIIB) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 22.6% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.76% / 30% · Interest income / Revenue 0.33% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 22.6% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.83% / 33% · Receivables / Mkt Cap (36m) 5.53% / 49% · Interest income / Revenue 0.33% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 22.6% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.83% / 33.33% · Receivables / Mkt Cap (24m) 5.53% / 33.33% · Interest income / Revenue 0.33% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 23.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 8.68% / 33.33% · Receivables / Avg Assets (4Q) 6.04% / 33.33% · Interest income / Revenue 0.33% / 5% | Pass |
| FTSE | Debt / Total Assets 24.0% / 33.33% · (Cash+ST Inv) / Total Assets 4.07% / 33.33% · (Cash+Recv) / Total Assets 9.95% / 33.33% · Interest income / Revenue 0.33% / 5% | Pass |
Yes. As of September 2026, Biogen Inc. (BIIB) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Biogen Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.33% of each dividend: Biogen Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Biogen Inc. (NASDAQ: BIIB) is a Healthcare company (Drug Manufacturers - General) with a market capitalization of $37.0B. The Maz Rating grades it against the other companies in its sector.
Biogen Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $250.10, Biogen Inc. trades at 106.6x trailing earnings, 3.6x sales and 2.0x book value, with an EV/EBITDA of 27.2. Over the last twelve months it generated about $10.2B of revenue and $347M of net income. It runs a gross margin of 70.0%, an operating margin of 7.6% and a net margin of 3.4%. It shows return on equity of 1.9%, return on invested capital of 2.2% and a free cash flow yield of 5.5%. On the balance sheet: a debt-to-equity ratio of 0.41 and a current ratio of 1.95. Over the past 52 weeks the share price ranged from $160.36 to $261.00, with a beta of 0.17.
Biogen Inc. does not currently pay a dividend.
49 Wall Street analyst ratings cover the stock: 33 Buy, 15 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.